Singapore pharmaceutical plant

Schering-Plough Corp. (Madison, NJ) has awarded the engineering, procurement, and construction management (EPC) contract for a new USD 100 million biotech plant to Jacobs Lend Lease, a joint venture of Jacobs Engineering Group Inc. (Pasadena, CA) and Bovis Lend Lease (London, UK). The companies plan to build the plant, which will produce a new hepatitis C drug, on a 12-acre site next an existing Schering-Plough bulk manufacturing plant in Tuas, Singapore. They have scheduled mid-2003 for start-up. The project includes construction of a four-story building block spanning 700,000 sq ft. It will contain administrative offices, laboratory facilities, a plant room, production space, and a warehouse. An additional utility block will include chiller units, a cooling tower, a tank farm, and plant facilities. Jacobs Lend Lease offices in Dublin, Ireland, and Singapore will share project front-end engineering and detailed design. The Singapore office will take charge of construction. Completion is expected within three-and-a-half years.

Previous articleICI relief valve repair
Next articleVenezuela to invest in natural gas